SOURCE: Conformia

March 24, 2008 08:00 ET

Conformia Presents Strategies for Implementing ISA88 Compliance Across Life Science Development Operations at World Batch Forum 2008

PHILADELPHIA, PA--(Marketwire - March 24, 2008) -


What:   Louis Ciabattoni, Senior Product Manager at Conformia Software,
        Inc., the leading provider of Product and Process Lifecycle
        Management (PPLM) software solutions, is presenting "Implementing
        ISA88 across Life Science Development Operations" at the 2008
        World Batch Forum. The session will provide best practice
        strategies for pharmaceutical organizations implementing an
        ISA88-compliant electronic development record application. Based
        on Conformia's experience as an observing member of the ISA88
        Workgroup and its work with the top 20 life science companies,
        Ciabattoni will summarize how to successfully rollout ISA88,
        present new ISA88 concepts found only in development and outline
        a straightforward mechanism for technology transfer of a U.S.
        Food and Drug Administration (FDA) approved product to commercial
        manufacturing.

Where:  World Batch Forum 2008 North American Conference
        Dolce Valley Hotel and Conference Center, Philadelphia, PA

When:   Tuesday, March 25, 4:30-5:00 p.m. EDT

Why:    ISA88 is an international standard for flexibility in production
        addressing the structure of the production process and for
        developing the control of equipment. Implementing the standard,
        however, is perceived as a challenge in most industries including
        the life sciences where the demand for greater accuracy, tighter
        controls and a higher bar of compliance are already creating
        significant demands on organizations. Even with new FDA
        recommendations for Pharmaceutical cGMP for the 21st Century, the
        industry has been slow in accepting the standard.

        Conformia addresses these pharmaceutical industry challenges head
        on with its PPLM software that enables organizations to save
        significant time and money through major improvements in product
        development operations. With Conformia's PPLM software,
        pharmaceutical organizations are enabled with a modern scaleable
        architecture to make technology transfer between Pharmaceutical
        R/D and Commercial Manufacturing more facile. Organizations gain
        a complete electronic development record (eDR), the ability
        to trace any problem back to its origin and regular compliance
        reports, on demand.

        Louis Ciabattoni will be available during the conference for press
        interviews. To schedule a briefing or a teleconference before or
        after the event, please contact conformia@schwartz-pr.com.

About Conformia

Conformia Software is the leading provider of product/process lifecycle management (PPLM) software solutions to Life Sciences. Conformia solutions enable companies to save significant time and money through major improvements in product/process development operations, while modernizing the core product/process lifecycle knowledge. Conformia's solutions are all browser based, built on modern SOA and JAVA J2EE. The company's solutions include platform for product/process lifecycle management (PPLM) as well as business applications for each major area of the product and process lifecycle, which help enhance operational visibility and traceability. Conformia offers an SAP-endorsed business solution and together, SAP and Conformia are building a bridge to support the lifecycle from development to manufacturing. For more information, go to www.conformia.com.

Conformia is a registered trademark of Conformia Software, Inc. SAP, SAP NetWeaver and other SAP products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of SAP AG in Germany and in several other countries all over the world. All other marks are the property of their respective holders. All other brands, products, or service names are or may be trademarks or service marks of their respective owners.

Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP's future financial results are discussed more fully in SAP's filings with the U.S. Securities and Exchange Commission ("SEC"), including SAP's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.

Contact Information